

AJIC Contents

American Journal of Infection Control

EDITORIAL

- APIC vision** 243
L Dickey

MAJOR ARTICLES

- Impact of COVID-19 pandemic on hospital onset bloodstream infections (HOBSI) at a large health system** 245
LK Sturm, K Saake, PB Roberts, FA Masoudi, and MG Fakih
- A comparative analysis of machine learning approaches to predict *C. difficile* infection in hospitalized patients** 250
S Panchavati, NS Zelin, A Garikipati, E Pellegrini, Z Iqbal, G Barnes, J Hoffman, J Calvert, Q Mao, and R Das
- How many lives do COVID vaccines save? Evidence from Israel** 258
R Arbel, CM Moore, R Sergienko, and J Pliskin
- Factors and reasons associated with low COVID-19 vaccine uptake among highly hesitant communities in the US** 262
S Khairat, B Zou, and J Adler-Milstein
- Facilitators of COVID-19 vaccine acceptance among Black and Hispanic individuals in New York: A qualitative study** 268
ZT Osakwe, JC Osborne, N Osakwe, and A Stefancic
- Vaccine breakthrough infections in veterans hospitalized with coronavirus infectious disease-2019: A case series** 273
PS Kim, RJ Schildhouse, S Saint, SF Bradley, S Chensue, N Houchens, and A Gupta
- Impact of COVID-19 on an infection prevention and control program, Iowa 2020-2021** 277
M Alsuhaibani, T Kobayashi, C McPherson, S Holley, AR Marra, A Trannel, A Dains, OJ Abosi, KE Jenn, H Meacham, L Sheeler, W Etienne, ME Kukla, M Wellington, MB Edmond, DJ Diekema, and JL Salinas
- Educating health professionals about COVID-19 with ECHO telementoring** 283
JG Katzman, K Thornton, N Sosa, L Tomedi, L Hayes, M Sievers, K Culbreath, K Norsworthy, C Martin, A Martinez, J Liu, and S Arora
- Hygienic monitoring in long-term care facilities using ATP, crAssphage, and human noroviruses to direct environmental surface cleaning** 289
JL Cannon, GW Park, B Anderson, C Leone, M Chao, J Vinjé, and AM Fraser

MICROBIAL SURVEILLANCE TESTING MADE EASY

Healthmark offers the One-Two Punch to Identify and Document the Efficacy of Your Endoscope Reprocessing

SCREEN WITH THE **NOW! TEST**

*Rapid Indicator of
Gram-Negative bacteria*

This immediate, practical screening test is available as a swab or flush method. Simply flush the lumen or swab the elevator mechanism of a flexible endoscope, such as a duodenoscope, and follow the procedure for gram-negative bacteria detection in less than 12 hours.

< 10 CFU



 **healthmark**

AUDIT WITH THE

FLEXIBLE ENDOSCOPE SAMPLING KIT


Surveillance tool for the random testing of duodenoscopes in compliance with FDA guidelines - In association with Nelson Laboratories



A simple and complete kit. After flushing and brushing the lumen and elevator mechanism of a duodenoscope, simply follow the procedure to have the sample solution & brush heads quickly sent to Nelson Laboratories - the leader in independent testing of flexible endoscopes. All tools are included for testing and shipment.


**NELSON
LABORATORIES**

Video engagement to improve handwashing duration: A longitudinal study assessing creative and messaging fatigue	295
L Ackermann, A Thum, K Meagher, D Molyneaux, R Neff, K Zabriskie, A Shimada, and J Riggio	
Personal protective equipment in Covid-19: Evidence-based quality and analysis of YouTube videos after one year of pandemic	300
G Gerundo, C Collà Ruvolo, B Puzone, G Califano, R La Rocca, V Parisi, M Capece, G Celentano, M Creta, G Rengo, D Leosco, P Abete, N Longo, V Mirone, and N Ferrara	
Using a human factors-centric approach to development and testing of a face shield designed for health care workers: A COVID-19 case study for process and outcomes	306
CE Kurtz, Y Peng, M Jesso, H Sanghavi, DR Kuehl, and SH Parker	
Fear for CoViD-19 and reluctance to work among health care workers during the epidemic, a prospective monocentric cohort study	312
M Moretti, D De Geyter, E Van Cutsem, S Van Laere, D Pierard, and SD Allard	
Evaluating the virucidal activity of four disinfectants against SARS-CoV-2	319
Y Huang, S Xiao, D Song, and Z Yuan	
Evaluation of virucidal activity of residual quaternary ammonium-treated surfaces on SARS-CoV-2	325
AG Caschera, J McAuley, Y Kim, D Purcell, J Rymenants, and DA Foucher	
SARS-CoV-2 Detection in air samples from inside heating, ventilation, and air conditioning (HVAC) systems- COVID surveillance in student dorms	330
S Sousan, M Fan, K Outlaw, S Williams, and RL Roper	
Long-term impact of contact precautions cessation for Methicillin-Resistant <i>Staphylococcus Aureus</i> (MRSA)	336
Z AlMohanna, AC Snavely, JP Viviano, and WE Bischoff	
PRACTICE FORUM	
A pseudo-outbreak of <i>Burkholderia cepacia</i> complex in a Kentucky hospital	342
CC Eldridge, AH Flinchum, D Thoroughman, and KB Spicer	
BRIEF REPORTS	
Methodology minute: Utilizing the RAND/UCLA appropriateness method to develop guidelines for infection prevention	345
KR Charles, L Hall, AJ Ullman, and JA Schults	
Prevalence and predictors of mask use on a large US university campus during the COVID-19 pandemic: A brief report	349
K Burnell, M Robbins, S Kulali, and EM Wells	
Daily use of public transportation and incidence of symptomatic COVID-19 among healthcare workers during the peak of a pandemic wave in Zurich, Switzerland	352
L Steinwender, D Holy, J Burkhard, and I Uçkay	
Developing an infection prevention program by leveraging the APIC competency model	355
K Cronin, C Silkaitis, A Mikolajczak, L Bardowski, and G Giannopoulos	



“How can I reduce HAI rates with limited staff and cost constraints?”

We can help.

Nozin® NOVASM programs help hundreds of facilities reverse rising MRSA/MSSA HAI rates with minimal staff, low cost, even net savings.

Our program outcomes show **infection rate reductions at 53% to 100% with savings up to \$1.4 million.**¹

We provide the tools, service and support you will need for effective colonization risk mitigation.

Start a free assessment at nozin.com/nova




#1 in Daily Patient Nasal Decolonization

Nozin®

NOVASM
PROGRAMS

LEADING WITH OUTCOMES

MRSA = methicillin-resistant *Staphylococcus aureus*, MSSA = methicillin-susceptible *Staphylococcus aureus*, HAI = Healthcare-Associated Infection. 1. References: nozin.com/clinical-outcomes. Outcomes reported by actual customers. Your results may vary. Nozin® Nasal Sanitizer antiseptic is for nasal decolonization. ©2022 Global Life Technologies Corp. All rights reserved. Made in USA. Nozin®, Nasal Sanitizer®, NOVASM are trademarks of Global Life Technologies Corp. Nozin® Nasal Sanitizer antiseptic is an OTC topical drug. No claim is made that it has an effect on any specific disease. Patent nos.: nozin.com/patents

- A description of the first *Candida auris*-colonized individuals in New York State, 2016-2017** 358
K Southwick, B Ostrowsky, J Greenko, E Adams, E Lutterlohthe NYS *C. auris* Team, RJ Denis, R Patel, R Erazo, R Fernandez, C Bucher, M Quinn, C Green, S Chaturvedi, L Leach, and Y Zhu
- Uptake and impact of vaccination against COVID-19 among healthcare workers-evidence from a multicentre study** 361
P Narayan, SK TS, MM BV, PA Ghorai, E Rupert, and DP Shetty
- COMMENTARY
- Long-term care and COVID-19: An equitable recovery** 364
MD Rubano, EF Kieffer, and EL Larson
-  **Article is available online** www.ajicjournal.org